摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5,11,17,23-tetra-tert-butyl-25-<(2-pyridylmethyl)oxy>-26-<<<2-(N-methylpyridinium)>methyl>oxy>-27,28-dihydroxycalix<4>arene iodide | 139606-53-4

中文名称
——
中文别名
——
英文名称
5,11,17,23-tetra-tert-butyl-25-<(2-pyridylmethyl)oxy>-26-<<<2-(N-methylpyridinium)>methyl>oxy>-27,28-dihydroxycalix<4>arene iodide
英文别名
5,11,17,23-tetratert-butyl-27-[(1-methylpyridin-1-ium-2-yl)methoxy]-28-(pyridin-2-ylmethoxy)pentacyclo[19.3.1.13,7.19,13.115,19]octacosa-1(24),3(28),4,6,9,11,13(27),15,17,19(26),21(25),22-dodecaene-25,26-diol;iodide
5,11,17,23-tetra-tert-butyl-25-<(2-pyridylmethyl)oxy>-26-<<<2-(N-methylpyridinium)>methyl>oxy>-27,28-dihydroxycalix<4>arene iodide化学式
CAS
139606-53-4
化学式
C57H69N2O4*I
mdl
——
分子量
973.09
InChiKey
OEUSXMVSWQGXES-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    9.35
  • 重原子数:
    64.0
  • 可旋转键数:
    6.0
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    75.69
  • 氢给体数:
    2.0
  • 氢受体数:
    5.0

反应信息

  • 作为产物:
    描述:
    syn-proximal-25,26-bis<(2-pyridylmethyl)oxy>-27,28-dihydroxycalix<4>arene碘甲烷 反应 24.0h, 以90%的产率得到5,11,17,23-tetra-tert-butyl-25-<(2-pyridylmethyl)oxy>-26-<<<2-(N-methylpyridinium)>methyl>oxy>-27,28-dihydroxycalix<4>arene iodide
    参考文献:
    名称:
    Functionalization of calix[4]arenes by alkylation with 2-(chloromethyl)pyridine hydrochloride
    摘要:
    The syntheses, structures, and conformations of nine of the 13 possible [(2-pyridylmethyl)oxy]calix[4]arene conformers obtainable by direct substitution on calix[4]arenes 1a,b are described. The conformer distribution in the exhaustive O-alkylation of 1a,b with 2-(chloromethyl)pyridine hydrochloride (PicCl.HCl) in N, N,N-dimethylformamide (DMF) is strongly affected by the base applied: NaH induces only cone conformers, while K2CO3 or Cs2CO3 lead preferentially to partial cone and/or 1,3-alternate conformers, depending on the para substituent of the starting calix[4]arene. Single-crystal X-ray analyses on tetra-O-alkylated cone 1k,1 and partial cone 2c have been conducted. Molecule 1k has a distorted cone conformation with pendant OCH2Py groups; a methanol of solvation is hydrogen bonded to one pyridine N atom and is exo to the calix cavity. The crystal structure of 11 contains two independent distorted cone shaped molecules per asymmetric unit which differ principally in the relative orientations of the OCH2Py groups. In the partial cone conformer 2c the conformation adopted is such that the pendant OCH2Py group of the rotated aryl ring lies in, and effectively fills, the calix cavity produced by the remaining three aryl rings; as in 1k a methanol of solvation is hydrogen bonded to a pyridine N atom exo to the calix cavity. Regioselective syn-proximal (1,2-) or syn-distal (1,3-) difunctionalization at the lower rim of calix[4]arenes has been also achieved. Syn-1,2-disubstituted derivatives have proved to be useful intermediates for the stereoselective synthesis of tri-O-alkylated cone conformers, calix[4]arenes with mixed ligating groups in the sequence AABB at the lower rim, for inherently chiral calix[4]arenes, and for the transfer of proximal regioselectivity from the lower to the upper rim. On the basis of stepwise O-alkylation of calix[4]arenes, and with the aid of MM2 calculations on the involved intermediates and their anions, a possible genesis of the various conformers is proposed.
    DOI:
    10.1021/jo00035a016
点击查看最新优质反应信息

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-(+)-5,5'',6,6'',7,7'',8,8''-八氢-3,3''-二叔丁基-1,1''-二-2-萘酚,双钾盐 (S)-盐酸沙丁胺醇 (S)-溴烯醇内酯 (S)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2-N-Fmoc-氨基甲基吡咯烷盐酸盐 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-3,3''-双([[1,1''-联苯]-4-基)-[1,1''-联萘]-2,2''-二醇 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-2,2'',3,3''-四氢-6,6''-二-9-菲基-1,1''-螺双[1H-茚]-7,7''-二醇 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (6,6)-苯基-C61己酸甲酯 (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,5R)-3,3a,8,8a-四氢茚并[1,2-d]-1,2,3-氧杂噻唑-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aS,8aR)-2-(吡啶-2-基)-8,8a-二氢-3aH-茚并[1,2-d]恶唑 (3aS,3''aS,8aR,8''aR)-2,2''-环戊二烯双[3a,8a-二氢-8H-茚并[1,2-d]恶唑] (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (3S,3aR)-2-(3-氯-4-氰基苯基)-3-环戊基-3,3a,4,5-四氢-2H-苯并[g]吲唑-7-羧酸 (3R,3’’R,4S,4’’S,11bS,11’’bS)-(+)-4,4’’-二叔丁基-4,4’’,5,5’’-四氢-3,3’’-联-3H-二萘酚[2,1-c:1’’,2’’-e]膦(S)-BINAPINE (3-三苯基甲氨基甲基)吡啶 (3-[(E)-1-氰基-2-乙氧基-2-hydroxyethenyl]-1-氧代-1H-茚-2-甲酰胺) (2′′-甲基氨基-1,1′′-联苯-2-基)甲烷磺酰基铝(II)二聚体 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,4S)-Fmoc-4-三氟甲基吡咯烷-2-羧酸 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环